Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.93−0.06 (-2.01%)
Close on Nov 12, 2026Market cap $27.43MP/E –Yield –
Adicet Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Adicet Bio's ebitda for the twelve months ending Sep 30, 2026 was -$90.54M. For fiscal 2025 it was -$115.73M. The highest annual figure on record is -$13.74M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$115.73M | – |
| FY2024 | Dec 31, 2024 | -$121.15M | – |
| FY2023 | Dec 31, 2023 | -$145.94M | – |
| FY2022 | Dec 31, 2022 | -$69.98M | – |
| FY2021 | Dec 31, 2021 | -$59.90M | – |
| FY2020 | Dec 31, 2020 | -$37.97M | – |
| FY2019 | Dec 31, 2019 | -$30.15M | – |
| FY2018 | Dec 31, 2018 | -$13.74M | – |
| FY2017 | Dec 31, 2017 | -$18.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$18.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$21.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.12M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$31.25M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.07M | -734.0% |
| Q4 FY2022 | Dec 31, 2022 | -$30.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.31M | – |
| Q1 FY2022 | Mar 31, 2022 | $5.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.33M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.03M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.16M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.19M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.52M | – |
See a number that looks wrong?